Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Merck
McKinsey
Medtronic
Dow

Last Updated: May 26, 2022

KARBINAL ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Karbinal Er patents expire, and what generic alternatives are available?

Karbinal Er is a drug marketed by Aytu and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in KARBINAL ER is carbinoxamine maleate. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the carbinoxamine maleate profile page.

US Patents and Regulatory Information for KARBINAL ER

KARBINAL ER is protected by two US patents.

Patents protecting KARBINAL ER

Modified release formulations containing drug-ion exchange resin complexes
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Modified release formulations containing drug--ion exchange resin complexes
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aytu KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aytu KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for KARBINAL ER

See the table below for patents covering KARBINAL ER around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2008140944 КОМПОЗИЦИИ С МОДИФИЦИРОВАННЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ КОМПЛЕКСЫ ЛЕКАРСТВЕННОЕ ВЕЩЕСТВО-ИОНООБМЕННАЯ СМОЛА See Plans and Pricing
South Korea 20080108520 MODIFIED RELEASE FORMULATIONS CONTAINING DRUG - ION EXCHANGE RESIN COMPLEXES See Plans and Pricing
Brazil PI0709606 formulações de liberação modificada contendo complexos fármaco-resina de troca iÈnica See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKesson
Express Scripts
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.